Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $5.72 to $6.31
• 50-Day Range: $5.85 to $13.00
• 52-Week Range: $5.70 to $17.80
• Volume: 650,860 shs
• Average Volume: 224,591 shs
• Market Capitalization: $133.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.50
• Consensus Rating: Moderate Buy

Enanta Pharmaceuticals Stock Analysis - MarketRank™

Enanta Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 195th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Enanta Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.73) to ($4.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enanta Pharmaceuticals is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enanta Pharmaceuticals is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enanta Pharmaceuticals has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.38% of the float of Enanta Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Enanta Pharmaceuticals has recently decreased by 4.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enanta Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Enanta Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

16.38% of the float of Enanta Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Enanta Pharmaceuticals has recently decreased by 4.44%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: N/A

News Sentiment

Enanta Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

Search Interest

1 people have searched for ENTA on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,846.00 in company stock.

Percentage Held by Insiders

13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENTA Stock Analysis - Frequently Asked Questions

How have ENTA shares performed this year?

Enanta Pharmaceuticals' stock was trading at $9.41 at the start of the year. Since then, ENTA shares have decreased by 33.3% and is now trading at $6.28.
View the best growth stocks for 2024 here.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its earnings results on Monday, November, 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.20. The business's revenue for the quarter was down 22.8% compared to the same quarter last year.

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' top institutional investors include Krensavage Asset Management LLC (7.07%), Geode Capital Management LLC (2.25%), State Street Corp (2.12%) and Caligan Partners LP (1.52%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Nathalie Adda, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance.
View institutional ownership trends.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/25/2024
• Today: 12/21/2024
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTA
• CUSIP: N/A
• CIK: 1177648
• Web: www.enanta.com
• Phone: (617) 607-0800
• Fax: 617-607-0530
• Employees: 145
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.50
• High Stock Price Target: $27.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +210.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-116,040,000.00
• Net Margins: -171.57%
• Pretax Margin: -174.15%
• Return on Equity: -73.02%
• Return on Assets: -28.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.21
• Quick Ratio: 5.21

Sales & Book Value

• Annual Sales: $67.64 million
• Price / Sales: 1.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.08 per share
• Price / Book: 1.03

Miscellaneous

• Outstanding Shares: 21,194,000
• Free Float: 18,303,000
• Market Cap: $133.10 million
• Optionable: Optionable
• Beta: 0.49